Stryker reported strong first quarter 2025 results, with net sales rising 11.9% year over year to $5.87 billion, and organic net sales up 10.1%.

Growth was driven by a 13.4% increase in MedSurg and Neurotechnology and 9.7% growth in Orthopaedics. Reported operating income declined 13.9% to $837 million due to increased selling, general, and administrative expenses. Reported EPS dropped 17.6% to $1.69, but adjusted EPS grew 13.6% to $2.84, reflecting continued margin expansion. Stryker raised its full-year 2025 organic net sales growth guidance to 8.5%–9.5% and maintained adjusted EPS guidance of $13.20–$13.45, inclusive of the dilutive impact from the Inari acquisition and approximately $200 million in expected tariffs.